Accepted Manuscript Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase 3 RESORCE trial Richard S. Finn, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, René Gerolami, Chiara Caparello, Roniel Cabrera, Charissa Chang, Weijing Sun, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Jordi Bruix, on behalf of the RESORCE Investigators, PII: S0168-8278(18)32018-X DOI: https://doi.org/10.1016/j.jhep.2018.04.010 Reference: JHEPAT 6941 To appear in: Journal of Hepatology Received Date: 1 December 2017 Revised Date: 9 March 2018 Accepted Date: 3 April 2018 Please cite this article as: Finn, R.S., Merle, P., Granito, A., Huang, Y-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Gerolami, R., Caparello, C., Cabrera, R., Chang, C., Sun, W., LeBerre, M-A., Baumhauer, A., Meinhardt, G., Bruix, J., on behalf of the RESORCE Investigators, Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase 3 RESORCE trial, Journal of Hepatology (2018), doi: https://doi.org/10.1016/j.jhep.2018.04.010 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.